CRSPCRSP
US • —
$54.54
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-89.1% YoY
Gross Margin
—
Health Score
3/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
CRISPR Therapeutics (CRSP) is a biotechnology company focused on developing gene-editing therapies based on the CRISPR/Cas9 platform, with its lead program, CTX001, targeting sickle cell disease and beta-thalassemia. The company operates in the high-growth, high-risk gene editing sector, where it competes as a pioneer alongside other biotechs like Intellia and Editas, yet faces significant clinical and regulatory hurdles. Its market cap tier cannot be determined from the available data, and financial scale is extremely limited, with TTM revenue of less than $1 million reflecting its pre-commercial stage. The company's defining characteristic is its foundational CRISPR/Cas9 patent estate and its strategic partnership with Vertex Pharmaceuticals, which provides co-development funding and commercialisation infrastructure for CTX001.
Financial Health
Net margin is reported at -13856.5% — note this figure may be distorted due to a one-time item or data anomaly, reflecting extreme losses relative to minimal revenue. Gross margin and prior-year margin data are unavailable, preventing a trend comparison...
Risk Assessment
- EARNINGS QUALITY — only 2 of the last 4 quarters beat analyst estimates, reflecting mixed guidance credibility and execution predictability.
- REVENUE DECELERATION — Revenue declined 89.1% year-over-year, a severe drop that signals the absence of a recurring commercial revenue stream.
- VALUATION — Price/Sales of 1304.16x is extreme for any company, reflecting a significant premium that demands near-perfect pipeline execution.
- FCF / CASH BURN — Free cash flow is not stated but negative, implied by negative net margin of -13,856.5% and negative return on equity, indicating ongoing cash burn with no revenue offset.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DATA COMPLETENESS — Several core fundamental metrics are missing (P/E, TTM revenue, FCF), increasing the uncertainty of any valuation assessment....
Net margin is reported at -13856.5% — note this figure may be distorted due to a one-time item or data anomaly, reflecting extreme losses relative to minimal revenue. Gross margin and prior-year margin data are unavailable, preventing a trend comparison. Debt/equity is 0.0x with a current ratio of 13.32x, indicating a fortress-like balance sheet with no debt and ample short-term liquidity to fund operations. Free cash flow is unavailable, but with no TTM revenue and a negative return on equity of -30.9%, the company is clearly burning through cash to fund research and development. This financial profile is typical for a pre-revenue biotech: strong liquidity provides runway, but the absence of revenue or profitability means the company relies entirely on equity financing and partnership cash flows to avoid dilution.
- EARNINGS QUALITY — only 2 of the last 4 quarters beat analyst estimates, reflecting mixed guidance credibility and execution predictability. - REVENUE DECELERATION — Revenue declined 89.1% year-over-year, a severe drop that signals the absence of a recurring commercial revenue stream. - VALUATION — Price/Sales of 1304.16x is extreme for any company, reflecting a significant premium that demands near-perfect pipeline execution. - FCF / CASH BURN — Free cash flow is not stated but negative, implied by negative net margin of -13,856.5% and negative return on equity, indicating ongoing cash burn with no revenue offset. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DATA COMPLETENESS — Several core fundamental metrics are missing (P/E, TTM revenue, FCF), increasing the uncertainty of any valuation assessment.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives